2/10
05:13 pm
dbvt
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting [Yahoo! Finance]
Low
Report
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting [Yahoo! Finance]
2/10
04:30 pm
dbvt
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
Medium
Report
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
2/9
06:00 pm
dbvt
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit [Yahoo! Finance]
Medium
Report
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit [Yahoo! Finance]
2/9
04:30 pm
dbvt
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
Medium
Report
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
2/8
02:04 am
dbvt
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at
Wall Street Z
Medium
Report
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at
Wall Street Z
2/5
04:30 pm
dbvt
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
Low
Report
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
1/19
01:53 am
dbvt
Why DBV Technologies (ENXTPA:DBV) Is Up 21.7% After Extending Its VIASKIN Peanut Funding Runway [Yahoo! Finance]
Low
Report
Why DBV Technologies (ENXTPA:DBV) Is Up 21.7% After Extending Its VIASKIN Peanut Funding Runway [Yahoo! Finance]
1/18
06:11 am
dbvt
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing [Yahoo! Finance]
Low
Report
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing [Yahoo! Finance]
1/16
06:11 pm
dbvt
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Low
Report
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
1/12
04:00 pm
dbvt
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Medium
Report
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
1/7
04:00 pm
dbvt
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Medium
Report
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
1/5
04:00 pm
dbvt
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Low
Report
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
12/20
09:41 pm
dbvt
Why DBV Technologies (ENXTPA:DBV) Is Up 11.8% After Positive Phase 3 Viaskin Peanut Patch Data [Yahoo! Finance]
High
Report
Why DBV Technologies (ENXTPA:DBV) Is Up 11.8% After Positive Phase 3 Viaskin Peanut Patch Data [Yahoo! Finance]
12/18
10:04 am
dbvt
DBV Technologies (NASDAQ:DBVT) was given a new $40.00 price target on by analysts at HC Wainwright.
Medium
Report
DBV Technologies (NASDAQ:DBVT) was given a new $40.00 price target on by analysts at HC Wainwright.
12/17
10:57 am
dbvt
DBV Technologies (NASDAQ:DBVT) was given a new $48.00 price target on by analysts at Cantor Fitzgerald.
Medium
Report
DBV Technologies (NASDAQ:DBVT) was given a new $48.00 price target on by analysts at Cantor Fitzgerald.
12/17
08:05 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a "market outperform" rating on the stock.
Medium
Report
DBV Technologies (NASDAQ:DBVT) had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a "market outperform" rating on the stock.
12/17
07:06 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/17
06:04 am
dbvt
Tesla, Netflix, Lennar, DBV Technologies, Micron, and More Stock Market Movers [Barron's]
Medium
Report
Tesla, Netflix, Lennar, DBV Technologies, Micron, and More Stock Market Movers [Barron's]
12/17
06:02 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
DBV Technologies (NASDAQ:DBVT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/16
10:11 pm
dbvt
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript [Seeking Alpha]
High
Report
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript [Seeking Alpha]
12/16
04:39 pm
dbvt
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
High
Report
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
12/16
04:05 pm
dbvt
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
High
Report
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
12/16
05:43 am
dbvt
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
12/15
07:20 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/14
07:02 pm
dbvt
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.